Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 181173
                    [Title] => Good News For Runners: Less ‘wear’ on joints, delayed disabilities
                    [Summary] => SORRENTO, Italy – New research among long-distance runners shows that osteoarthritis (OA), often called "wear and tear" arthritis, is not caused by "wear" alone.


At a symposium sponsored by Boehringer Ingelheim here last week, Prof. Jim Fries, of Stanford University, USA, presented new data showing that long-distance runners in the study actually developed disability much more slowly than non-exercisers. They reached a given level of disability 12 years later in life than non-exercisers, and enjoyed regular pain-free activity.


                    [DatePublished] => 2002-10-24 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 127573
                    [Title] => Meloxicam is safe, says study
                    [Summary] => PRAGUE — New data presented recently at the 16th European League Against Rheumatism (EULAR) Congress showed that the risk of heart attacks, other cardiac events and renal toxicity in patients taking the nonsteroid anti-inflammatory (NSAID) meloxicam (Mobic) is low. 


The result was similar for patients taking meloxicam and two other commonly prescribed NSAIDs. Moreover, no effects on bleeding time were observed in healthy volunteers with meloxicam at higher than recommended doses.


                    [DatePublished] => 2001-07-23 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 83639
                    [Title] => New osteoarthritis clinical trial okays anti-inflammatory drug
                    [Summary] => PRAGUE – In a unique managed care clinical trial, Mobic (meloxicam), designed to relieve the signs and symptoms of osteoarthritis, showed significantly greater "patient success" than other commonly used prescription nonsteroid anti-inflammatory drugs (NSAIDs).


The randomized study, which compared Mobic to "usual care," or whatever prescription-NSAID patients’ individual physicians selected as their osteoarthritis treatment, was presented for the first time at the Annual European Congress of Rheumatology in this city. 


                    [DatePublished] => 2001-07-09 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

MOBIC

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 181173
                    [Title] => Good News For Runners: Less ‘wear’ on joints, delayed disabilities
                    [Summary] => SORRENTO, Italy – New research among long-distance runners shows that osteoarthritis (OA), often called "wear and tear" arthritis, is not caused by "wear" alone.


At a symposium sponsored by Boehringer Ingelheim here last week, Prof. Jim Fries, of Stanford University, USA, presented new data showing that long-distance runners in the study actually developed disability much more slowly than non-exercisers. They reached a given level of disability 12 years later in life than non-exercisers, and enjoyed regular pain-free activity.


                    [DatePublished] => 2002-10-24 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 127573
                    [Title] => Meloxicam is safe, says study
                    [Summary] => PRAGUE — New data presented recently at the 16th European League Against Rheumatism (EULAR) Congress showed that the risk of heart attacks, other cardiac events and renal toxicity in patients taking the nonsteroid anti-inflammatory (NSAID) meloxicam (Mobic) is low. 


The result was similar for patients taking meloxicam and two other commonly prescribed NSAIDs. Moreover, no effects on bleeding time were observed in healthy volunteers with meloxicam at higher than recommended doses.


                    [DatePublished] => 2001-07-23 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 83639
                    [Title] => New osteoarthritis clinical trial okays anti-inflammatory drug
                    [Summary] => PRAGUE – In a unique managed care clinical trial, Mobic (meloxicam), designed to relieve the signs and symptoms of osteoarthritis, showed significantly greater "patient success" than other commonly used prescription nonsteroid anti-inflammatory drugs (NSAIDs).


The randomized study, which compared Mobic to "usual care," or whatever prescription-NSAID patients’ individual physicians selected as their osteoarthritis treatment, was presented for the first time at the Annual European Congress of Rheumatology in this city. 


                    [DatePublished] => 2001-07-09 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Good News For Runners: Less ‘wear’ on joints, delayed disabilities

October 24, 2002 - 12:00am

SORRENTO, Italy – New research among long-distance runners shows that osteoarthritis (OA), often called "wear and tear" arthritis, is not caused by "wear" alone. At a symposium sponsored...

Science and Environment

Meloxicam is safe, says study

July 23, 2001 - 12:00am

PRAGUE — New data presented recently at the 16th European League Against Rheumatism (EULAR) Congress showed that the risk of heart attacks, other cardiac events and renal toxicity in patients taking the nonsteroid...

Science and Environment

New osteoarthritis clinical trial okays anti-inflammatory drug

July 9, 2001 - 12:00am

PRAGUE – In a unique managed care clinical trial, Mobic (meloxicam), designed to relieve the signs and symptoms of osteoarthritis, showed significantly greater "patient success" than other commonly...

Science and Environment